Jon E. Angell

Array ( [id] => 12642168 [patent_doc_number] => 20180105887 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-04-19 [patent_title] => MOLECULAR PATHOGENESIS OF MICROCARCINOMA OF THE THYROID [patent_app_type] => utility [patent_app_number] => 15/788305 [patent_app_country] => US [patent_app_date] => 2017-10-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8544 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15788305 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13289533 [patent_doc_number] => 10155946 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-12-18 [patent_title] => Particle-nucleic acid conjugates and therapeutic uses related thereto [patent_app_type] => utility [patent_app_number] => 15/728474 [patent_app_country] => US [patent_app_date] => 2017-10-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 12 [patent_no_of_words] => 10469 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 75 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15728474 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12139480 [patent_doc_number] => 20180017563 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-01-18 [patent_title] => 'USE OF ISOCITRATE DEHYDROGENASE 1 AS A DIAGNOSTIC AND PROGNOSTIC BIOMARKER AND THERAPEUTIC TARGET FOR LUNG CANCERS' [patent_app_type] => utility [patent_app_number] => 15/719356 [patent_app_country] => US [patent_app_date] => 2017-09-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 9746 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15719356 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15102651 [patent_doc_number] => 10472627 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-11-12 [patent_title] => Natural antisense and non-coding RNA transcripts as drug targets [patent_app_type] => utility [patent_app_number] => 15/716093 [patent_app_country] => US [patent_app_date] => 2017-09-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 36 [patent_no_of_words] => 38112 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 120 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15716093 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12151825 [patent_doc_number] => 20180023086 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-01-25 [patent_title] => 'Compositions and Methods for Inhibiting Gene Expression of Factor XII' [patent_app_type] => utility [patent_app_number] => 15/715765 [patent_app_country] => US [patent_app_date] => 2017-09-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 35392 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15715765 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14712701 [patent_doc_number] => 20190247414 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-15 [patent_title] => BLOOD-BRAIN BARRIER PERMEABLE HETERODUPLEX NUCLEIC ACID [patent_app_type] => utility [patent_app_number] => 16/335017 [patent_app_country] => US [patent_app_date] => 2017-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34424 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16335017 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14743569 [patent_doc_number] => 20190254958 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-22 [patent_title] => DRUG DELIVERY USING APTAMER CONSTRUCT [patent_app_type] => utility [patent_app_number] => 16/333982 [patent_app_country] => US [patent_app_date] => 2017-09-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10469 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 91 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16333982 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12185745 [patent_doc_number] => 20180044682 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-15 [patent_title] => 'TREATMENT OF HYPERHIDROSIS' [patent_app_type] => utility [patent_app_number] => 15/709249 [patent_app_country] => US [patent_app_date] => 2017-09-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 3248 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15709249 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12219453 [patent_doc_number] => 20180057813 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-01 [patent_title] => 'COMPOSITIONS AND METHODS FOR NUCLEIC ACID TRANSFER' [patent_app_type] => utility [patent_app_number] => 15/690526 [patent_app_country] => US [patent_app_date] => 2017-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 13842 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15690526 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12857923 [patent_doc_number] => 20180177815 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-28 [patent_title] => MIRNAS AS NOVEL THERAPEUTIC ADJUVANTS AND BIOMARKERS FOR THE PROGNOSIS AND TREATMENT OF DRUG RESISTANT BREAST CANCERS [patent_app_type] => utility [patent_app_number] => 15/675877 [patent_app_country] => US [patent_app_date] => 2017-08-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9689 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15675877 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16320161 [patent_doc_number] => 10780108 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-09-22 [patent_title] => RNAi agents for Hepatitis B virus infection [patent_app_type] => utility [patent_app_number] => 15/766036 [patent_app_country] => US [patent_app_date] => 2017-08-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44345 [patent_no_of_claims] => 67 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15766036 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12126549 [patent_doc_number] => 20180010128 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-01-11 [patent_title] => 'OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAs' [patent_app_type] => utility [patent_app_number] => 15/664005 [patent_app_country] => US [patent_app_date] => 2017-07-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 136722 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15664005 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14372511 [patent_doc_number] => 20190160168 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-30 [patent_title] => IMMUNE ADJUVANT FOR CANCER [patent_app_type] => utility [patent_app_number] => 16/320660 [patent_app_country] => US [patent_app_date] => 2017-07-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11704 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 83 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16320660 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14119721 [patent_doc_number] => 10246710 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-04-02 [patent_title] => Double strand RNA as molecular biopesticides for RNA interference through feeding in the hemipteran invasive insect pest, brown marmorated stink bug [patent_app_type] => utility [patent_app_number] => 15/657646 [patent_app_country] => US [patent_app_date] => 2017-07-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 40 [patent_no_of_words] => 14653 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15657646 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16009295 [patent_doc_number] => 20200179490 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-11 [patent_title] => COLLAGEN-MIMETIC PEPTIDE MEDIATED DELIVERY OF NUCLEIC ACID CARRIERS FOR EFFICIENT DELIVERY FROM COLLAGEN [patent_app_type] => utility [patent_app_number] => 16/316378 [patent_app_country] => US [patent_app_date] => 2017-07-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26408 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16316378 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12002175 [patent_doc_number] => 20170306329 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-26 [patent_title] => 'METHODS FOR TREATING EYE DISORDERS' [patent_app_type] => utility [patent_app_number] => 15/645751 [patent_app_country] => US [patent_app_date] => 2017-07-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 54087 [patent_no_of_claims] => 73 [patent_no_of_ind_claims] => 32 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15645751 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14712703 [patent_doc_number] => 20190247415 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-15 [patent_title] => METHODS AND MATERIALS FOR ACTIVATING MUSCLE REMODELING [patent_app_type] => utility [patent_app_number] => 16/317662 [patent_app_country] => US [patent_app_date] => 2017-07-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3166 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16317662 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12607428 [patent_doc_number] => 20180094306 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-04-05 [patent_title] => Nucleic Acid Amplification [patent_app_type] => utility [patent_app_number] => 15/642746 [patent_app_country] => US [patent_app_date] => 2017-07-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27468 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15642746 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14762461 [patent_doc_number] => 10392618 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-08-27 [patent_title] => Micro-RNA family that modulates extracellular matrix genes and uses thereof [patent_app_type] => utility [patent_app_number] => 15/640220 [patent_app_country] => US [patent_app_date] => 2017-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 37 [patent_no_of_words] => 28456 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15640220 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13703419 [patent_doc_number] => 20170362664 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-21 [patent_title] => TREATMENT OF ANGIOGENESIS DISORDERS [patent_app_type] => utility [patent_app_number] => 15/629971 [patent_app_country] => US [patent_app_date] => 2017-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22219 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15629971 [rel_patent_id] =>[rel_patent_doc_number] =>)